Picture loading failed.

pdf downloadAAV protocol Download
pdf downloadAAV User Manual Download


AAV serotype 6 (AAV capsid 6) system - Introduction

GeneMedi's AAV6 Vector System (AAV serotype 6 helper-free packaging plasmids system) is including AAV6 Rep-Cap plamid (AAV6-RC plasmid, or called AAV-RC6 plasmid), AAV helper plasmid and AAV expression vectors (overexpression or shRNA).

GeneMedi's AAV expression vectors have been inserted with differernt expression cassettes, containing kinds of verified protomters and reporters including GFP, zsgreen, RFP, mcherry and luciferase. The GeneMedi's AAV expression vectors have been proved very suitalble for unique gene overexpression or shRNA-mediated knock-down (also called RNAi (RNA interference ). You can also achieve gene knock-out(KO) or gene editing using our Crispr-cas9-gRNA AAV expression vector.

AAV6 Rep-Cap plamid supplies the AAV2 Rep(replication) proteins and the AAV6 capsid protein.

The tissue tropism of AAV6 vector has been validated in neuron (CNS), lung, liver, heart and muscle, with potential applications in tissue-specific gene therapy.

AAV6 has also been proved a high transduction efficency in T cell, wtih potential applications in T cell-mediated cancer immunotherapies, including Chimaeric antigen receptor T(CAR-T) and TCR engineered T (TCR-T) cell therapy.

Product Name Contents Price(In USD) Qty (Quantity) Sum(In USD)
AAV6 vector system 1. AAV6 Rep-Cap plasmid, 5ug
2. AAV Helper Plasmid, 5ug
3. pGMAAV-CMV-MCS-3flag-T2A-ZsGreen
(P-AAVV-B01), 5ug
Expression vector default to B01, if you need more expression vector, pleasae click →AAV Expression Vector list
1280
Shipping Cost: 130.00
Total:

AAV6 vector tissue tropism and gene transduction (serotype-specific AAV infection)

The tissue tropism of AAV6 vector has been validated in neuron (CNS), lung, liver, heart and muscle, with potential applications in tissue-specific gene therapy.

AAV6 has also been proved a high transduction efficency in T cell, wtih potential applications in T cell-mediated cancer immunotherapies, including Chimaeric antigen receptor T(CAR-T) and TCR engineered T (TCR-T) cell therapy.

Picture loading failed.
Figure. Selected transduction results of AAV in vitro (in 293T cell line)

Virus and titer: AAV1/AAV6/AAV8/AAV-Rh10/AAV-DJ/AAV9-GFP, 1×1012 vg/ml
Cells: HEK-293T
MOI: MOI=1×104
Determine assay: 36 hours post infection, immunofluorescence microscopy


Other AAV vector system


AAV1 vector system

AAV2 vector system

AAV2 variant(Y444F) vector system

AAV2 variant (Y272F,Y444F,Y500F,Y730F) vector system

AAV2 variant(Y444F,Y730F,Y500F,Y272F,Y704F,Y252F) vector system

AAV2 variant(AAV2.7m8) vector system

AAV5 vector system

AAV8 vector system

AAV8-1m vector system

AAV8-2m vector system



AAV8-3m vector system

AAV9 vector system

AAV-Rh10 vector system

AAV-DJ vector system

AAV-Dj8 vector system

AAV2-Retro (Retrograde) vector system

AAV9-PHP.B vector system

AAV9-PHP.eB vector system

AAV9-PHP.S vector system